The Fort Worth Press - Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

USD -
AED 3.672498
AFN 65.000023
ALL 82.324126
AMD 360.954502
ANG 1.790403
AOA 917.999843
ARS 1546.245702
AUD 1.480845
AWG 1.8
AZN 1.69704
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.6704
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.427285
CDF 2315.000247
CHF 0.838445
CLF 0.025355
CLP 997.910145
CNY 6.67175
CNH 6.670535
COP 3319.96
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.146958
DJF 178.554905
DKK 6.781825
DOP 60.996961
DZD 137.215041
EGP 53.666204
ERN 15
ETB 164.576405
EUR 0.90722
FJD 2.27435
FKP 0.756889
GBP 0.756925
GEL 2.589897
GGP 0.756889
GHS 11.756648
GIP 0.756889
GMD 73.999788
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.845525
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 331.085501
IDR 18267
ILS 3.21895
IMP 0.756889
INR 94.05615
IQD 1520.102326
IRR 1913737.493849
ISK 123.920313
JEP 0.756889
JMD 158.434973
JOD 0.709006
JPY 159.380496
KES 130.049912
KGS 87.435502
KHR 4119.418691
KMF 446.999884
KPW 900.00035
KRW 1334.339988
KWD 0.31147
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.830219
MMK 2100.274506
MNT 3605.662913
MOP 8.103614
MRU 40.552456
MUR 47.810103
MVR 15.402503
MWK 1738.739965
MXN 18.58995
MYR 4.092495
MZN 63.843843
NAD 16.951268
NGN 1343.350271
NIO 36.903315
NOK 9.574275
NPR 151.114437
NZD 1.81089
OMR 0.385095
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.933502
PKR 277.274459
PLN 3.997335
PYG 6223.068898
QAR 3.655265
RON 4.851503
RSD 106.693821
RUB 82.54671
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.875029
SDG 601.501052
SEK 10.075065
SGD 1.288355
SHP 0.752984
SLE 23.049758
SLL 20969.503664
SOS 573.051087
SRD 37.490172
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.869465
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392598
TTD 6.806306
TWD 32.987012
TZS 2651.411999
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25747.5
VUV 120.320092
WST 2.810586
XAF 595.097238
XAG 0.021048
XAU 0.000259672138
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 595.097238
XPF 108.186074
YER 236.549835
ZAR 16.97378
ZMK 9001.198917
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.086045
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death

Text size:

MIAMI, FLORIDA / ACCESS Newswire / February 26, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced compelling new preclinical findings demonstrating that Telomir-1 fully reverses calcium dysregulation-an often-overlooked yet fundamental driver of cell death, aging, and disease progression-in multiple human cell lines."

In addition to restoring calcium homeostasis, the study further confirmed that Telomir-1 reverses oxidative stress and provides robust cellular protection against stress-induced damage. Cells treated with Telomir-1 remained viable and functional despite exposure to extreme oxidative stress, while untreated cells exhibited signs of degeneration and death. By blocking calcium influx, Telomir-1 is believed to preserve mitochondrial function, prevent the activation of cell death pathways, and stabilize key cellular mechanisms that support longevity and disease resistance.

These findings build upon prior research showing that Telomir-1 also fully reverses oxidative stress (ROS overproduction), reinforcing its potential as a broad-spectrum therapeutic for aging-related diseases. By restoring intracellular calcium balance, reducing oxidative stress, and protecting mitochondrial integrity and functions, Telomir-1 may directly prevent cellular damage at the root cause, addressing the fundamental mechanisms that drive neurodegeneration, metabolic disorders, inflammatory diseases, and viral-induced complications.

"These findings are too significant to ignore," said Erez Aminov, CEO of Telomir. "Telomir-1 has demonstrated the ability to reverse a fundamental process that underlies cellular death, aging and disease. I am committed to ensuring that we advance this science as quickly as possible, bringing Telomir-1 closer to clinical use. The urgency of these discoveries is clear, and we welcome those who share our vision to join us in progressing this breakthrough treatment."

Study Design and Key Findings

The study was conducted using human keratinocyte (HaCaT) and retinal (ARPE-19) cell lines to assess the effects of Telomir-1 on calcium homeostasis, oxidative stress, and cellular survival after exposure to hydrogen peroxide (H₂O₂), iron (Fe²⁺), and copper (Cu²⁺), which are known to induce oxidative stress, mitochondrial dysfunction and cellular damage.

Calcium Regulation in Human Cells

  • Cells were exposed to H₂O₂, Fe²⁺, or Cu²⁺ to induce intracellular calcium overload.

  • Telomir-1 reversed calcium dysregulation in a concentration-dependent manner, restoring homeostasis across the studied cell lines.

  • The reduction in calcium influx was observed within 10-20 minutes post-exposure, confirming Telomir-1's ability to rapidly stabilize calcium signaling.

Oxidative Stress Reduction and Cell Protection

  • Cells challenged with high levels of Fe²⁺ and Cu²⁺ showed increased oxidative stress and ROS production.

  • Telomir-1 significantly reduced ROS levels, mitigating oxidative damage at the mitochondrial level.

  • Cell viability assays confirmed that Telomir-1 protected against oxidative stress-induced cell death, reinforcing its role in cellular defense and longevity.

Prevention of Cell Death and Preservation of Mitochondrial Integrity

  • Cells treated with Telomir-1 remained viable and functional despite exposure to extreme oxidative stress, whereas untreated cells exhibited signs of damage and decline.

  • Telomir-1 is believed to stabilize mitochondrial function, thereby preventing stress signals that trigger apoptosis and necrosis.

  • This suggests Telomir-1 has the potential to prevent several steps and processes involved in the progressive cellular deterioration that drives aging and disease.

Mitochondria: The Link Between Calcium Dysregulation, Oxidative Stress, and Disease

Mitochondria are often called the powerhouses of the cell, but they also act as a major trigger for cellular death when dysregulated. Both oxidative stress (ROS overproduction) and calcium dysregulation disrupt mitochondrial function, accelerating aging and disease progression.

  • Oxidative Stress & ROS: Excess ROS damages mitochondrial DNA, triggering chronicinflammation, neurodegeneration, and organ failure.

  • Calcium Dysregulation: Mitochondria regulate intracellular calcium levels, but an overload of calcium leads to mitochondrial collapse, driving cell death in a variety of diseases such as Alzheimer's, Type 2 diabetes, and metabolic disorders.

  • Aging & Cellular Decay: Mitochondrial dysfunction contributes to telomere shortening, stem cell exhaustion, and systemic aging.

By fully reversing ROS production and calcium dysregulation, Telomir-1 is believed to protect mitochondrial integrity, and to prevents premature cell death. This unlocks new possibilities for treating aging-related diseases.

Telomir-1's Potential Across Age-Related and Degenerative Diseases

Neurodegenerative Diseases: A New Approach to Alzheimer's

  • Calcium overload and oxidative stress contribute to neuronal death and cognitive decline.

  • Telomir-1 reversed calcium dysregulation and blocked oxidative damage, key mechanisms in Alzheimer's disease and neurodegeneration.

Age-Related Macular Degeneration (AMD) & Retinal Disease

  • Oxidative stress and calcium dysregulation drive photoreceptor and retinal cell death in AMD and diabetic retinopathy.

  • Telomir-1 stabilized intracellular calcium levels and protected retinal cells from apoptosis, suggesting strong potential for preventing vision loss.

Type 2 Diabetes (T2D) & Metabolic Dysfunction

  • Calcium balance is crucial for insulin secretion, and its dysregulation impairs pancreatic beta-cell function.

  • Telomir-1 restored calcium balance, reduced oxidative stress, and protected pancreatic beta cells, offering potential for metabolic disease treatment

Wilson's Disease & Metal-Induced Oxidative Stress

  • Copper accumulation in Wilson's disease disrupts calcium homeostasis, leading to neurotoxicity.

  • Telomir-1 reversed calcium imbalance and oxidative damage, highlighting a novel therapeutic strategy for metal-related degenerative disorders.

Viral-Induced Inflammation: Avian Flu and Other Viruses

  • Calcium dysregulation and oxidative stress contribute to hyperinflammation and tissue damage in severe viral infections.

  • Telomir-1 demonstrated the ability to reduce calcium overload and oxidative stress, suggesting it may help mitigate viral-induced inflammatory damage.

"These results highlight the remarkable potential of Telomir-1 to target one of the most overlooked drivers of cellular aging-calcium dysregulation and mitochondrial dysfunction," said Dr. Angel, Chief Scientific Advisor at Telomir. "By restoring calcium balance, reversing oxidative stress, and preventing cell death, we are not just addressing individual diseases but unlocking a fundamental mechanism that could redefine how we approach age-related conditions and longevity."

Telomir is advancing preclinical studies to bring Telomir-1 into human trials, with the goal of developing a first-in-class therapy for neurodegeneration, retinal disease, Type 2 diabetes, Wilson's disease, and longevity-based interventions.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1, starting with ongoing research in animals and then in humans.

Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.

Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Contact Information

Helga Moya
[email protected]
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc.



View the original press release on ACCESS Newswire

A.Nunez--TFWP